Hepatitis C virus (HCV) infects 170 million people worldwide, and is a leading cause of liver-related mortality due to development of cirrhosis and hepatocellular carcinoma. Treatment of chronic HCV infection is now possible with combinations of oral, directly acting antiviral agents (DAAs), which do not require exogenous injectable interferon (IFN) to achieve HCV eradication. Treatment failure with DAA therapy typically occurs due to HCV relapse after treatment, although mechanisms are poorly understood. Furthermore, the necessary duration of treatment required to achieve a sustained virologic response (SVR), synonymous with HCV eradication, differs between people, and may be influenced by host immunity. The goal of this project is to discover host immune correlates and mechanisms of treatment outcome during IFN-free DAA therapy for HCV. To accomplish this, the applicant will utilize clinical samples collected during therapy to assess differences between subjects who achieve SVR versus relapse in markers of (1) immune activation and interferon sensitivity in peripheral blood, (2) the liver proteome before and after treatment, with analysis using bioinformatics platforms, and (3) in vitro sensitivity of lymphocytes and monocytes during DAA therapy to exogenous immune stimulation, asking whether such stimulation at the end of treatment could prevent relapse. The applicant, Dr. Meissner, is a physician-scientist in the Division of Infectious Diseases at the Medical University of South Carolina, with a secondary appointment in the Department of Microbiology and Immunology. His long-term career goal is to become an independent investigator studying mechanisms of inter-individual immune variability in response to chronic viral infections, in order to better understand disease progression and differential response to therapies. To facilitate his transition to investigative independence, he is seeking to broaden the multidisciplinary nature of his investigations by developing expertise in tissue proteomics, in vitro study of immunity, and use of bioinformatic tools. The environment for the success of Dr. Meissner is provided by (1) a multi-disciplinary team with a track record of mentoring and expertise needed to support the project, (2) departmental and divisional support with protected time to develop a career as a physician scientist, (3) availability of a unique set f clinical samples collected during IFN-free therapy for chronic HCV infection, and (4) active clinical participation in an Infectious Diseases clinic providing care to patients infected with HC alone or co-infected with HCV and the human immunodeficiency virus (HIV). Identification of correlates and mechanisms of treatment relapse during DAA therapy for HCV infection will provide timely contributions to an active clinical field that is changing dynamically with new treatment options. This training will enable Dr. Meissner to achieve his long-term goal of becoming an independent investigator leading multidisciplinary efforts to study variability in the host response to chronic viral infections including HCV, HIV, and hepatitis B virus, with the aim of understanding and improving clinical outcomes.
Chronic infection with hepatitis C virus (HCV) affects up to 180 million people worldwide and 3-4 million people in the United States, and if untreated, can result in cirrhosis and hepatocellular carcinoma. Treatment of HCV is now possible with oral medications that directly inhibit viral proteins, resulting in eradication of HCV, although relapse of HCV after treatment can occur for reasons that are not clear or easy to predict. This study will utilize samples collected during HCV treatment to investigate why some patients relapse after treatment, with the aim of improving our ability to both predict and prevent relapse, thereby optimizing clinical outcomes and preventing the sequelae of chronic infection.
|Meissner, Eric G (2018) The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression? Clin Infect Dis 67:878-880|
|Orr, Cody; Aartun, Johannes; Masur, Henry et al. (2018) Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. J Viral Hepat :|
|Meissner, Eric G (2017) Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era. Curr Opin Gastroenterol 33:120-127|
|Meissner, Eric G; Kohli, Anita; Higgins, Jeanette et al. (2017) Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection. Hepatol Commun 1:586-594|